

Electronic Acknowledgement Receipt

EFS ID:	29632564
Application Number:	14958259
International Application Number:	
Confirmation Number:	3046
Title of Invention:	METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS
First Named Inventor/Applicant Name:	Bruce Scharschmidt
Customer Number:	101325
Filer:	Christopher Lee Marion/Lauren Wilson
Filer Authorized By:	Christopher Lee Marion
Attorney Docket Number:	HOR0026-201TC2-US
Receipt Date:	28-JUN-2017
Filing Date:	03-DEC-2015
Time Stamp:	12:35:49
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$ 160
RAM confirmation Number	062817INTEFSW00010943504297
Deposit Account	
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	

--	--	--	--	--	--

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Statutory disclaimers per MPEP 1490	20170628_Disclaimer_966_pat ent.pdf	133277 a770b0bb5cbca4319ec0b6c6d602d55c67a62a34	no	1

Warnings:

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	30737 38c4cb1e9ed9ba5372b9d03b82ccc23e4cc9f63f	no	2
---	----------------------	--------------	---	----	---

Warnings:

Information:

Total Files Size (in bytes):			164014		
-------------------------------------	--	--	--------	--	--

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a)	
Name of Patentee Horizon Therapeutics, LLC	Docket Number (Optional) HOR0026-201TC2-US
Patent Number 9,326,966	Date Patent Issued May 3, 2016
Title of Invention METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS	
I hereby disclaim the following complete claims in the above identified patent: _____ 12, 14, and 15	
The extent of my interest in said patent is (if assignee of record, state liber and page, or reel and frame, where assignment is recorded): 100% Owner (Reel 039640, Frame 0886)	
The fee for this disclaimer is set forth in 37 CFR 1.20(d).	
<input type="checkbox"/> Patentee claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> Small entity status has already been established in this case, and is still proper. <input type="checkbox"/> A check in the amount of the fee is enclosed. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. <u>50-4297</u> .	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
Signed at <u>St. Louis</u> , State of <u>Missouri</u> , this <u>28th</u> day of <u>June</u> 20 <u>17</u> .	
<u>/Chris Marion/</u> Signature	<u>L0931</u> Registration Number, if applicable
<u>Chris Marion</u> Typed or printed name of patentee/ attorney or agent of record	<u>314-812-8020</u> Telephone Number
<u>17014 New College Avenue, Suite 201</u> Address	
<u>St. Louis, MO 63040</u> City, State, Zip Code or Foreign Country as applicable	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.